Arkolith/Insider Trading/AMLX/Form 4

Klee Justin B.

Co-Chief Executive Officer, DirectorAmylyx Pharmaceuticals, Inc. (AMLX) · full profile →Form 4 · filed Feb 6, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 5, 2025Option exercise(M)36K$1.57$57K3.2M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 5, 2025Option exercise(M)36K—$00

Transaction Codes

M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-25-015701) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML